LY-2109761: Difference between revisions
CSV import |
CSV import |
||
| Line 21: | Line 21: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:LY-2109761 structure.png|LY-2109761 | |||
</gallery> | |||
Revision as of 01:08, 20 February 2025
LY-2109761 is a small molecule inhibitor that targets transforming growth factor beta receptor types I and II (TGFβRI/II). It has been studied for its potential use in the treatment of cancer, particularly in inhibiting the growth and spread of tumor cells.
Mechanism of Action
LY-2109761 works by inhibiting the kinase activity of TGFβRI/II. This prevents the phosphorylation of SMAD proteins, which are crucial for the transmission of TGFβ signals from the cell surface to the nucleus. By blocking this signaling pathway, LY-2109761 can inhibit the growth and spread of tumor cells.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of LY-2109761 in the treatment of various types of cancer. These trials have shown promising results, with LY-2109761 demonstrating significant anti-tumor activity in preclinical models of pancreatic cancer and hepatocellular carcinoma.
Potential Side Effects
As with any drug, LY-2109761 may cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. However, these side effects are generally mild and manageable with appropriate medical intervention.
Future Research
Further research is needed to fully understand the potential benefits and risks of LY-2109761. This includes additional clinical trials to evaluate its efficacy in other types of cancer, as well as studies to explore its mechanism of action in more detail.
